News & Publications

On October 27, 2017, Laura A. Stokowski, of Medscape, released the details from an interview with Dr. Paul Nghiem regarding Merkel cell carcinoma and its defining characteristics, proper management, and recent advances in treatment options. Use of the "AEIOU" characteristics can help in identifying...

Merkel cell carcinoma (MCC) is a rare but highly aggressive skin cancer with neuroendocrine features. MCC pathogenesis is associated with either the presence of Merkel cell polyomavirus or chronic exposure to ultraviolet light (UV), which can cause a characteristic pattern of multiple DNA mutations....

On October 19th, 2017, Danielle Bucco of OncLive released an article pertaining to the advantages of treating Merkel cell carcinoma with immunotherapy. Historically, chemotherapy has been used as the first line of treatment. However, recent statistics highlight the difference in progression-free sur...

On Thursday October 19th, Dr. Paul Nghiem had the opportunity to meet with Dr. J. Helen Leonard. He shares his experience below. "After collaborating for over a decade, I, finally got to meet Dr J. Helen Leonard here in Brisbane, Australia, the city in which she started the world’s first resear...

On October 2, 2017, Jake Siegel, of The UW Medicine Huddle, released an article on Dr. Paul Nghiem's path to studying  and specializing in Merkel cell carcinoma.  As Nghiem states, "MCC had morphed from a chore to a moderately interesting subject to a two-decade whirlwind of clinical, basic and tr...

Overview On September 11, 2017 in Seattle, over 260 patients, family members, clinicians, scientists, and trainees from across the United States gathered for the 12th annual Merkel cell carcinoma Dinner Meeting. They enjoyed a lovely buffet dinner, music, lab tours and a presentation on the statu...

Merkel cell carcinoma (MCC) is a rare skin cancer caused by Merkel cell polyomavirus (MCPyV) infection and/or ultraviolet radiation–induced somatic mutations. The presence of tumor-infiltrating lymphocytes is evidence that an active immune response to MCPyV and tumor-associated neoantigens occurs ...

We are passing along information that may be of interest to some MCC patients and families… The Seattle MCC Support Group will host a special facilitated discussion on September 11 prior to the Nghiem Merkel Dinner Meeting. This discussion session is entitled: "GRIEF AND GRATTITUDE" SEPTE...

Objectives: CD200 expression has been well studied in hematopoietic malignancies; however, CD200 expression has not been well-characterized in neuroendocrine neoplasms. We examined CD200 expression in 391 neuroendocrine neoplasms from various anatomic sites. Methods: Tissue blocks containing pulmona...

https://www.usatoday.com/story/opinion/2017/08/06/clinical-trial-saved-my-life-could-save-yours-stan-collender-column/513055001/